2026-2034年全球勃起功能障礙治療市場規模、佔有率、趨勢和成長分析報告

預計到 2034 年，治療勃起功能障礙的市場規模將從 2025 年的 41.1 億美元成長至 90.4 億美元，2026 年至 2034 年的複合年成長率為 9.14%。

受文明病增加的推動，全球勃起功能障礙治療市場正穩定成長。人們對男性健康問題的日益關注，加速了全球相關治療的普及。人口老化導致男性人口不斷成長，也顯著促進了市場需求的擴大。學名藥的普及提高了治療的可近性和可負擔性。這些因素共同推動了市場的持續成長。

主要促成因素包括糖尿病、高血壓和心血管疾病盛行率的上升。壓力大的生活方式和久坐的習慣正在增加勃起功能障礙的發生率。線上藥局和遠端醫療平台正在改善藥物取得途徑。製藥公司正在投資研發副作用較少的改良配方。開發中國家醫療保健覆蓋範圍的擴大進一步刺激了需求。

鑑於對先進治療方法的持續研究，前景依然樂觀。研發出藥效更持久、療效更佳的藥物將帶來成長機會。社會對療法的接受度提高將有助於提升其普及率。新興市場蘊藏著巨大的未開發潛力。藥物輸送系統的持續創新將塑造未來的市場擴張。

目錄

第1章：引言

第2章執行摘要

第3章 市場變數、趨勢與框架

• 市場譜系展望
• 滲透率和成長前景分析
• 價值鏈分析
• 法律規範
  • 標準與合規性
  • 監管影響分析
• 市場動態
  • 市場促進因素
  • 市場限制因素
  • 市場機遇
  • 市場挑戰
• 波特五力分析
• PESTLE分析

第4章 全球勃起功能障礙治療市場：依藥物類型分類

• 市場分析、洞察與預測
• Sildenafil
• 他達拉非
• 伐地那非
• 阿伐那菲爾
• 其他

第5章 全球勃起功能障礙治療市場：依給藥途徑分類

• 市場分析、洞察與預測
• 口服錠劑
• 注射藥物
• 外用藥物

第6章 全球勃起功能障礙治療市場：依最終使用者分類

• 市場分析、洞察與預測
• 醫院
• 診所
• 居家照護

第7章 全球勃起功能障礙治療市場：依地區分類

• 區域分析
• 北美市場分析、洞察與預測
  • 美國
  • 加拿大
  • 墨西哥
• 歐洲市場分析、洞察與預測
  • 英國
  • 法國
  • 德國
  • 義大利
  • 俄羅斯
  • 其他歐洲國家
• 亞太市場分析、洞察與預測
  • 印度
  • 日本
  • 韓國
  • 澳洲
  • 東南亞
  • 其他亞太國家
• 拉丁美洲市場分析、洞察與預測
  • 巴西
  • 阿根廷
  • 秘魯
  • 智利
  • 其他拉丁美洲國家
• 中東和非洲市場分析、洞察與預測
  • 沙烏地阿拉伯
  • UAE
  • 以色列
  • 南非
  • 其他中東和非洲國家

第8章 競爭情勢

• 最新趨勢
• 公司分類
• 供應鏈和銷售管道合作夥伴（根據現有資訊）
• 市場佔有率和市場定位分析（基於現有資訊）
• 供應商情況（基於現有資訊）
• 策略規劃

第9章：公司簡介

• 主要公司的市佔率分析
• 公司簡介
  • Teva Pharmaceutical Industries Ltd
  • SK Chemicals Co. Ltd
  • Cristalia Produtos QuAfA-Micos FarmacAfAªUticos Ltd
  • Futura Medical Plc
  • GlaxoSmithKline PLC
  • Petros Pharmaceuticals
  • Lupin Limited
  • Glenmark Pharmaceuticals Limited
  • Cipla Ltd
  • Endo International Plc

The Erectile Dysfunction Drugs Market size is expected to reach USD 9.04 Billion in 2034 from USD 4.11 Billion (2025) growing at a CAGR of 9.14% during 2026-2034.

The global erectile dysfunction drugs market is growing steadily due to increasing prevalence of lifestyle-related disorders. Rising awareness about men's health issues is encouraging treatment adoption worldwide. The growing aging male population significantly contributes to demand growth. Availability of generic alternatives has improved affordability and accessibility. These factors collectively drive consistent market expansion.

Key drivers include rising cases of diabetes, hypertension, and cardiovascular diseases. Stressful lifestyles and sedentary habits are increasing the incidence of erectile dysfunction. Online pharmacies and telehealth platforms are improving drug accessibility. Pharmaceutical companies are investing in improved formulations with fewer side effects. Expanding healthcare access in developing countries is further supporting demand.

Future prospects remain favorable with ongoing research into advanced treatment options. Development of longer-lasting and more effective medications offers growth opportunities. Increased social acceptance of treatment will support higher adoption rates. Emerging markets present significant untapped potential for manufacturers. Continuous innovation in drug delivery systems will shape future market expansion.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Drug Type

• Sildenafil
• Tadalafil
• Vardenafil
• Avanafil
• Others

By Mode of Administration

• Oral Tablets
• Injectables
• Topical Medications

By End User

• Hospitals
• Clinics
• Homecare

COMPANIES PROFILED

• Teva Pharmaceutical Industries Ltd, SK Chemicals Co Ltd, Cristalia Produtos Qumicos Farmacuticos Ltd, Futura Medical plc, GlaxoSmithKline PLC, Petros Pharmaceuticals, Lupin Limited, Glenmark Pharmaceuticals Limited, Cipla Ltd, Endo International plc
• We can customise the report as per your requirements.

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET: BY DRUG TYPE 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Drug Type
• 4.2. Sildenafil Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Tadalafil Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.4. Vardenafil Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.5. Avanafil Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.6. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET: BY MODE OF ADMINISTRATION 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Mode Of Administration
• 5.2. Oral Tablets Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Injectables Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.4. Topical Medications Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET: BY END USER 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast End User
• 6.2. Hospitals Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. Clinics Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.4. Homecare Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET: BY REGION 2022-2034(USD MN)

• 7.1. Regional Outlook
• 7.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.2.1 By Drug Type
  • 7.2.2 By Mode Of Administration
  • 7.2.3 By End User
  • 7.2.4 United States
  • 7.2.5 Canada
  • 7.2.6 Mexico
• 7.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.3.1 By Drug Type
  • 7.3.2 By Mode Of Administration
  • 7.3.3 By End User
  • 7.3.4 United Kingdom
  • 7.3.5 France
  • 7.3.6 Germany
  • 7.3.7 Italy
  • 7.3.8 Russia
  • 7.3.9 Rest Of Europe
• 7.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.4.1 By Drug Type
  • 7.4.2 By Mode Of Administration
  • 7.4.3 By End User
  • 7.4.4 India
  • 7.4.5 Japan
  • 7.4.6 South Korea
  • 7.4.7 Australia
  • 7.4.8 South East Asia
  • 7.4.9 Rest Of Asia Pacific
• 7.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.5.1 By Drug Type
  • 7.5.2 By Mode Of Administration
  • 7.5.3 By End User
  • 7.5.4 Brazil
  • 7.5.5 Argentina
  • 7.5.6 Peru
  • 7.5.7 Chile
  • 7.5.8 South East Asia
  • 7.5.9 Rest of Latin America
• 7.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.6.1 By Drug Type
  • 7.6.2 By Mode Of Administration
  • 7.6.3 By End User
  • 7.6.4 Saudi Arabia
  • 7.6.5 UAE
  • 7.6.6 Israel
  • 7.6.7 South Africa
  • 7.6.8 Rest of the Middle East And Africa

Chapter 8. COMPETITIVE LANDSCAPE

• 8.1. Recent Developments
• 8.2. Company Categorization
• 8.3. Supply Chain & Channel Partners (based on availability)
• 8.4. Market Share & Positioning Analysis (based on availability)
• 8.5. Vendor Landscape (based on availability)
• 8.6. Strategy Mapping

Chapter 9. COMPANY PROFILES OF GLOBAL ERECTILE DYSFUNCTION DRUGS INDUSTRY

• 9.1. Top Companies Market Share Analysis
• 9.2. Company Profiles
  • 9.2.1 Teva Pharmaceutical Industries Ltd
  • 9.2.2 S.K. Chemicals Co. Ltd
  • 9.2.3 Cristalia Produtos QuAfA-Micos FarmacAfAªUticos Ltd
  • 9.2.4 Futura Medical Plc
  • 9.2.5 GlaxoSmithKline PLC
  • 9.2.6 Petros Pharmaceuticals
  • 9.2.7 Lupin Limited
  • 9.2.8 Glenmark Pharmaceuticals Limited
  • 9.2.9 Cipla Ltd
  • 9.2.10 Endo International Plc